0112 Fin and Deal QTs
BioCentury & Getty Images


Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

Jan 13, 2021 | 1:58 AM GMT

Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230

Read the full 396 word article

How to gain access

Continue reading with a
two-week free trial.